In striking contrast, vaccination with antigen expressing genes usually fails to induce significant immune responses. Various methods are under evaluation to augment the potency of DNA vaccines, such as combination with gene delivery devices to increase the transfection of cells or to target the DNA or with the adjuvants which enhance inflammatory cytokine expression. [9] [10] [11] [12] [13] [14] The extent of DNA degradation by extracellular deoxyribonucleases is unknown, but degradation could be considerable. It follows that approaches to protect DNA from the extracellular biological milieu and thereby introduce it into cells more efficiently, should contribute to optimal DNA vaccine design. In this context, not only efficient gene delivery devices but also immunostimulatory adjuvants are essential for augmentation of DNA vaccination.
Interestingly, the sequence composition of plasmid DNA itself also has been shown to increase the potency of the DNA vaccine. 12) This is because the bacterial DNA sequences result in the plasmid which possesses different methylation pattern from mammalian DNA. Bacterial oligonucleotides having the sequence purine-purine-cytosineguanosine-pyrimidine-pyrimidine, in which the CpG sequence is unmethylated, can activate innate immune system, resulting in an augmentation of the antigen-specific immunity. 15) Recently, it was established that the innate immune system of vertebrates recognizes non methylated CpG motifs flanked by specific bases in bacterial DNA as a danger signal through toll-like receptor 9 (TLR9) expressed on the antigen presenting cells. [16] [17] [18] The cytokine profile induced by CpG motifs in vitro is consistent with their ability to induce a Th1-biased immune response when used as an adjuvant in vaccine formulations. 19) Therefore, CpG motifs may have potential as adjuvants in protein-and DNA-based vaccine formulations. 20) CpG DNA is internalized via a clathrin dependent endocytic pathway and rapidly moves into a lysosomal compartment. 29) Since it has been known that TLR9 is localized in lysosomal compartment, CpG containing plasmids should be delivered to endosome-lysosome pathway even if plasmids were degraded in endosomes. Recently, several reports are suggested that TLR9 is expressed in ER prior to stimulation and translocate to a CpG containing lysosomal compartment for ligand binding and signal transduction. 29) In this context, with a view of plasmid based DNA vaccine development, CpG DNA targeting to translocating TLR9 is more useful to avoid endosomal DNA degradation.
Previously, we developed a highly unique antigen delivery carrier, fusogenic liposomes (FL), which consist of conventional liposomes and ultra-violet inactivated Sendai virus-derived accessory proteins. [21] [22] [23] [24] 25) However, improvement of the efficacy of the FL-mediated gene delivery system is important for the development of a DNA vaccine.
In this study, we, therefore, created a novel genetic immunization system combined with a CpG-containing plasmid backbone and FL. The principal aim of this study was to induce potent antigen-specific immunity to the antigens encoded in the plasmid encapsulated in FL and combined with the CpG motif and a model antigen, chicken egg ovalbumin (OVA), thereby formulating a DNA vaccine.
MATERIALS AND METHODS
Animals and Cells Male C57BL/6 (H-2 b ) mice, 7 weeks old, were purchased from SLC Inc. (Hamamatsu, Shizuoka, Japan). EL4 (Tohoku University, Sendai, Japan) is a C57BL/6 T lymphoma and EG7 is an ovalbumin (OVA)-transfected clone of EL4. IC21 cell is a C57BL/6 macrophage clone, H-2Kb. CD8OVA1.3 (provided by Dr. Clifford V. Harding, Case Western Reserve University, Cleveland, OH, U.S.A.) is a T-T hybrid cell, which is specific for OVA257-264-Kb. EL4 and IC21 cells were grown in RPMI1640 medium supplemented with 10% FCS. The CTLL-2 cells were maintained in RPMI1640 medium supplemented with 10% FCS and 1 U/ml human recombinant IL-2. The EG7 cells were maintained in RPMI1640 medium supplemented with 10% FCS and 400 mg/ml G418. CD8OVA1.3 was grown in a DMEM medium supplemented with 10% FCS. All culture media were purchased from Invitrogen (Carlsbad, CA, U.S.A.) and supplemented with non-essential amino acids, antibiotics, and 5ϫ10 5 mM 2-mercaptoethanol (2-ME).
Plasmids The EcoRI fragment of pAc-neo-OVA was cloned into the EcoRI site of pBluescriptII KS(Ϫ), resulting in pBluescriptII KS(Ϫ)/OVA. To construct an OVA gene expression vector, the BamHI/SalI fragment of pBluescript II KS(Ϫ)/OVA was ligated into BamHI/SalI cut pCMV-script (Stratagene), resulting in pCMV-script/OVA ( Fig. 1 ), which is driven by cytomegalovirus promoter and contains a SV40 poly(A) signal. This pCMV-script/OVA containing 13 repeats of the CpG motif, was named pOVACpG13. Furthermore, the plasmid containing 16 CpG motif repeats, pOVACpG16, was constructed as follows. SspI and AlwNI fragments of the pGL3-control vector (Promega) were ligated into pCMVscript digested with AlwNI and blunt ended, resulting in the CpG-enhanced vector, pCMV-script/CpG(ϩ). Then, the BamHI/SalI fragment of pBluescript II KS(Ϫ)/OVA was introduced into the BamHI/SalI digested pCMV-script/CpG (ϩ). This plasmid contained 16 CpG motif repeats. Methylated plasmids were prepared by SssI treatment for 4 h at 37°C. These methylated plasmids were used for experiments after purification by phenol/chloroform precipitation.
Preparation of fusogenic liposome plasmid vector containing unilamellar liposomes was prepared by a modified reverse-phase evaporation method using 46 mmol of lipids (egg phosphatidylcholine : L-a -dimyristryl phosphatidic acid : cholesterolϭ5 : 1 : 4, molar ratio). After three cycles of freezing and thawing, the liposomes were sized by extrusion through a 0.8 mm polycarbonate membrane (Nucleopore; Coaster, Cambridge, MA, U.S.A.) and pelleted by ultracentrifugation to remove un-encapsulated plasmids. Then, FLs encapsulating pCMV-script/OVA were prepared by fusing the liposomes with UV (2000 J/cm 2 )-inactivated Sendai virus as described. [21] [22] [23] [24] The amount of plasmid DNA encapsulated within the liposomes was determined by means of fluorometric assay using 3,5-diaminobenzoic acid.
Proliferative Responses of Antigen-Specific T Cells from Immunized Mice Fourteen days after final immunization, lymphocytes were obtained from spleen. B cells were then depleted by using goat anti-mouse IgG (H&L)-coupled micro beads and a MACS column (Miltenyi Biotec, Sunnyvale, CA, U.S.A.). Purified T cells were cultured at a density of 2ϫ10 5 IL-12 Expression Analysis by ELISA IL-12 levels in culture supernatants of Ag stimulated splenocytes were determined by a cytokine-specific ELISA. Briefly, splenocytes from immunized mice were cultured with 1 mg/ml OVA (or various indicated concentrations). Culture supernatants were harvested 48 h after incubation, and the levels of IL-12 were determined by an IL-12-specific ELISA kit (Biosource). The concentration of cytokines was calculated by standard curves obtained according to the instructions provided by the manufacturer.
In Vitro CTL Induction and Cytotoxic Assay C57BL/ 6 mice (7 weeks old, male, H-2 b ) were immunized twice at 2 week intervals with 50 mg of naked or 5 mg of Fusogenic liposome encapsulated pOVACpG13 or pOVACpG16, respectively. Spleen cells from immunized or non-immunized mice were recovered 14 d after the last immunization and were stimulated in vitro with mitomycin C treated EG7 cells for 5 d. The cytotoxic activity of these effector cells was tested on 51 Cr-labeled target cells, OVA-expressed EG7 cells, and EL4 as a control, at different effector/target ratios. A cytotoxicity assay was conducted in triplicate. The maximum release was determined by adding 1% Triton X-100 to the target cells. A spontaneous release was obtained in the case of target cells incubated without effector cells. EL4 cells were used as control for specificity. The released radioactivity was measured in the supernatant. The specific lysis was determined as follows: Tumor Challenge Experiments C57BL/6 mice (7 weeks old, male, H-2b) were immunized s.c. at the tail base twice at 2 week intervals with 50 mg of naked or 5 mg of fusogenic liposome encapsulated pOVACpG13 or pOVACpG16. Fourteen days after the last immunization (day 0), 1ϫ10 6 OVA expressing EG7 cells were intradermally injected. Six to 13 mice were used for each experimental group. Tumor survival in tumor bearing mice was monitored weekly. Mice that developed tumors larger than 4000 mm 3 were considered to have developed lethal tumors.
RESULTS

In Vitro Enhancement of IL-12 Expression by CpG-Enhanced Vectors Combined with FL
Initially we evaluated the immunostimulatory effect of CpG-enhanced vector encapsulated in FL by IL-12 production (Fig. 1) . ELISA analysis showed that IL-expression of FL/pOVACpG16-stimulated splenocytes tended to enhance IL-12 production compared with non-CpG enhanced vector (pOVACpG13) containing FL. In addition, methylated plasmid vector encapsulated in FL or empty FL did not enhance IL-12 expression. These results clearly showed that CpG-enhanced vectors retained their immunostimulatory effect even when encapsulated in FL, and IL-12 expression increased depending on the number of CpG motifs.
Vaccination with CpG-Enhanced Vector Combined with FL Significantly Enhances Antigen Specific T Cell Mediated Immune Responses in Vaccinated Mice
Examination of antigen-specific proliferation of lymphocytes in immunized mice (Fig. 2) indicated that FL/pOVACpG16 vaccination dramatically enhanced proliferation. On the other hand, FL/pOVACpG13-or naked CpG-enhanced or non-enhanced vector immunization did not induce antigen-specific proliferation. These results indicated that the combination of CpG immuno stimulatory sequences and FL significantly enhanced antigen specific T cell proliferation under a very low dose (5 mg). Next, the immunogenicity of FL/pOVACpG16 was tested by CTL assay (Fig. 3) . The best response was obtained for pOVACpG16 combined with FL, which exhibited ex vivo killing of ca. 40% at an E : T ratio of 50. The corresponding killing obtained by pOVACpG13 combined with FL was in the range of 30%.
Protection against the Growth of OVA-Expressing Tumors in Mice Vaccinated with CpG-Enhanced Vectors by FL To determine whether the observed enhancement in antigen-specific T cell mediated immunity translated to a significant anti-tumor immunity and prolonged survival, we performed an in vivo tumor protection experiment using an OVA expressing tumor-model, EG7. As shown in Fig. 4 , 70% of mice receiving the pOVACpG16 vaccine combined with FL survived 90 d after the EG7 challenge. In contrast, the survival rate of unvaccinated mice and mice receiving pOVACpG13 or pOVACpG16 alone or a combination vaccine of pOVACpG13 and FL was less than 40%. A two-fold improvement was observed in the response of mice treated with a prophylactic vaccine treatment consisting of pOVACpG16 combined with FL. These results indicated that the combination of CpG enhanced vectors and FL was a more effective genetic immunization system for prophylactic tumor vaccine. In the present study, we demonstrated that a combination of CpG-enhanced vectors and FL strengthened IL-12 expression by splenocytes from naïve mice, and this approach enhanced the potency of DNA vaccines using OVA as a model antigen, leading to effective OVA specific T cell proliferation, CTL responses, and prophylactic anti-tumor effects. Our previous study showed that immunization of mice with conventional OVA expression vector, pOVACpG13 using FL, induced antigen-specific antibodies and strong CTL responses. 25) In the present study, we utilized CpG immunostimulatory sequences to enhance FL-mediated DNA vaccination therapy. The results demonstrated that CpG introduction was effective for in vitro inflammatory cytokine production by APCs and this leads to dramatically enhanced proliferation of antigen-specific T cell proliferation, because IL-12 production and OVA specific T cell proliferation was significantly weaker in conventional CpG containing plasmid vector (pOVACpG13) or even in combination with FL in immunized mice.
Generally, the CpG motif, even in a plasmid backbone, stimulates APCs via TLR9 receptor signaling. 16, 17) Although these activation mechanisms are available to the endocytosis pathway, 26) previous studies have not reported any investigations of immunostimulatory ability of directly introduced CpG motifs via membrane fusion. Recent report suggested that TLR is expressed in ER prior to stimulation, and translocate to lysosomal compartment through cytosolic compartment by inflammatory stimuli. 29) So we hypothesized that CpG enhanced plasmid in cytosol could bind to TLR9, which is translocating from ER to lysosome through cytosol. Another hypothesis is that DNAs adsorbed on FL or released from FL may interact with TLR9. Overall, although our data indicate that the direct introduction of CpG-enhanced vectors via membrane fusion retained their stimulatory effects, detailed studies are needed to clarify activation mechanisms. Our data indicated that antigen specific T cell proliferation and CTL responses were more effective than the combination of FL and conventional pOVACpG13 in vaccinated mice. When challenged with OVA-expressing EG7 tumors, mice immunized with the CpG-enhanced vector combined with FL exhibited prolonged survival compared with conventional vector immunized groups, even when combined with FL.
Although the anti-tumor effects presented in Fig. 4 are somewhat striking, they hold little relevance to immunological therapy against tumors. We should have tested their vaccines in a therapeutic mode (tumor first and vaccine after) and not solely in a prophylactic fashion. Moreover, these experiments do not address the issue of potential immunological tolerance to real tumor antigens, which in many cases are also expressed to some extent by normal cells, since OVA is a totally foreign antigen. Studies conducted using a real tumor antigen in murine models, such as TRP2 for B16 melanoma, 27) P1A for P815 mastocytoma, 28) or anything equivalent, could potentially provide additional information that better simulates actual conditions. In summary, our findings indicate that the introduction of three CpG immunostimulatory sequences and FL is able to enhance inflammatory cytokines and elicit more effective antigen-specific T cell activity and prophylactic anti-tumor effects in vivo than a previously developed conventional plasmid backbone (pOVACpG13 and FL combination vaccine). This approach may be promising for future vaccine development to control cancer, which expresses self antigens, or infectious diseases, and may be particularly useful in patients with reduced immune responses, particularly human immunodeficiency virus (HIV) or human T cell leukemia virus (HTLV)-infected patients. Studies are in progress to clarify the efficacy of FL mediated genetic immunization systems on tumor-associated antigens and virus-related antigen expression vectors.
